UBS AM’s MoonLake Immunotherapeutics MLTX Stock Holding History

UBS AM’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06M	Buy	105,739 +31,577	+43%	+$572K	﹤0.01%	2035
2026 Q1	$1.38M	Buy	+74,162	New	+$1.23M	﹤0.01%	2201
2025 Q3	–	Sell	-19,164	Closed	-$905K	–	2473
2025 Q2	$905K	Sell	19,164 -24,640	-56%	-$1M	﹤0.01%	2409
2025 Q1	$1.71M	Buy	43,804 +1,568	+4%	+$67.6K	﹤0.01%	2068
2024 Q4	$2.29M	Buy	42,236 +6,422	+18%	+$328K	﹤0.01%	1971
2024 Q3	$1.81M	Buy	35,814 +17,580	+96%	+$824K	﹤0.01%	2086
2024 Q2	$802K	Buy	18,234 +3,003	+20%	+$127K	﹤0.01%	2471
2024 Q1	$765K	Hold	15,231	–	–	﹤0.01%	2145
2023 Q4	$920K	Buy	15,231 +53	+0.3%	+$2.73K	﹤0.01%	2070
2023 Q3	$865K	Buy	+15,178	New	+$838K	﹤0.01%	2030

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS AM's MLTX Position: Q2 2026 in Review

UBS AM increased its MoonLake Immunotherapeutics (MLTX) stake by 43% in Q2 2026, buying an estimated $572K and bringing the position to 105,739 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2035.

UBS AM first reported a position in MLTX in Q3 2023 and has held it in 10 quarters since. The position peaked at $2.29M in Q4 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

UBS AM held 105,739 shares of MoonLake Immunotherapeutics worth $2.06M as of Q2 2026.
UBS AM bought 31,577 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $572K.
MoonLake Immunotherapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2035 holding.
UBS AM first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 10 quarters since.
UBS AM's MoonLake Immunotherapeutics position peaked at $2.29M in Q4 2024.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.